Considerations in Treatment Planning for Esophageal Cancer

Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8 Hulscher, 2002, Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus, N Engl J Med, 347, 1662, 10.1056/NEJMoa022343 2002, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial, Lancet, 359, 1727, 10.1016/S0140-6736(02)08651-8 Walsh, 1996, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma, N Engl J Med, 335, 462, 10.1056/NEJM199608153350702 Herskovic, 1992, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 326, 1593, 10.1056/NEJM199206113262403 Hosch, 2001, Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance, J Clin Oncol, 19, 1970, 10.1200/JCO.2001.19.7.1970 Minsky, 1999, Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus, Int J Radiat Oncol Biol Phys, 43, 517, 10.1016/S0360-3016(98)00463-5 Minsky, 2002, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy, J Clin Oncol, 20, 1167, 10.1200/JCO.20.5.1167 Bosset, 1997, Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus, N Engl J Med, 337, 161, 10.1056/NEJM199707173370304 Urba, 2001, Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J Clin Oncol, 19, 305, 10.1200/JCO.2001.19.2.305 Krasna, 2006 Kwa, 1998, Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis, Radiother Oncol, 48, 61, 10.1016/S0167-8140(98)00020-6 Yorke, 2002, Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy, Int J Radiat Oncol Biol Phys, 54, 329, 10.1016/S0360-3016(02)02929-2 Oetzel, 1995, Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis, Int J Radiat Oncol Biol Phys, 33, 455, 10.1016/0360-3016(95)00009-N Graham, 1999, Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC), Int J Radiat Oncol Biol Phys, 45, 323, 10.1016/S0360-3016(99)00183-2 Hernando, 2001, Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer, Int J Radiat Oncol Biol Phys, 51, 650, 10.1016/S0360-3016(01)01685-6 Lingos, 1991, Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy, Int J Radiat Oncol Biol Phys, 21, 355, 10.1016/0360-3016(91)90782-Y Law, 2004, Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer, Ann Surg, 240, 791, 10.1097/01.sla.0000143123.24556.1c Wang, 2006, Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery, Int J Radiat Oncol Biol Phys, 64, 692, 10.1016/j.ijrobp.2005.08.002 Chandra, 2005, Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer, Radiother Oncol, 77, 247, 10.1016/j.radonc.2005.10.017 2000, Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials, Lancet, 355, 1757, 10.1016/S0140-6736(00)02263-7 Ng, 2002, Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger, J Clin Oncol, 20, 2101, 10.1200/JCO.2002.08.021 Eriksson, 2000, Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: Analysis with the relative seriality model, Radiother Oncol, 55, 153, 10.1016/S0167-8140(00)00166-3 Pera, 2005, Epidemiology of esophageal adenocarcinoma, J Surg Oncol, 92, 151, 10.1002/jso.20357 Lavrenkov, 2005, Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer, Radiother Oncol, 77, 1, 10.1016/j.radonc.2005.09.016 Nishioka, 2002, Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas, Int J Radiat Oncol Biol Phys, 53, 1051, 10.1016/S0360-3016(02)02854-7 Leong, 2006, A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer, Radiother Oncol, 78, 254, 10.1016/j.radonc.2006.02.014 Moureau-Zabotto, 2005, Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma, Int J Radiat Oncol Biol Phys, 63, 340, 10.1016/j.ijrobp.2005.02.039 Konski, 2005, The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma, Int J Radiat Oncol Biol Phys, 61, 1123, 10.1016/j.ijrobp.2004.07.717 Vrieze, 2004, Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?, Radiother Oncol, 73, 269, 10.1016/j.radonc.2004.10.001 van Westreenen, 2003, Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography, Ann Surg Oncol, 10, 1100, 10.1245/ASO.2003.03.005 Lowe, 2005, Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer, Mol Imaging Biol, 7, 422, 10.1007/s11307-005-0017-0 Shrikanthan, 2005, Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging, Clin Nucl Med, 30, 695, 10.1097/01.rlu.0000178244.55482.2a Bural, 2005, Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET, Clin Nucl Med, 30, 182, 10.1097/00003072-200503000-00008 Weber, 2001, Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 19, 3058, 10.1200/JCO.2001.19.12.3058 Downey, 2003, Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial, J Clin Oncol, 21, 428, 10.1200/JCO.2003.04.013 Song, 2005, FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer, Int J Radiat Oncol Biol Phys, 63, 1053, 10.1016/j.ijrobp.2005.03.033 Wieder, 2005, Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction, J Nucl Med, 46, 2029 Westerterp, 2005, Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review, Radiology, 236, 841, 10.1148/radiol.2363041042 Hong D, Lunagomez S, Kim EE, et al: Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104:1620-1626, 15 Jarritt, 2005, Use of combined PET/CT images for radiotherapy planning: Initial experiences in lung cancer, Br J Radiol, 28, S33, 10.1259/bjr/14526714 Mell, 2003, A survey of intensity-modulated radiation therapy use in the United States, Cancer, 98, 204, 10.1002/cncr.11489 Wu, 2003, Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas, Int J Radiat Oncol Biol Phys, 56, 573, 10.1016/S0360-3016(02)04617-5 Fu, 2004, Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma, World J Gastroenterol, 10, 1098, 10.3748/wjg.v10.i8.1098